NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02657434,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132),https://clinicaltrials.gov/study/NCT02657434,,COMPLETED,"This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.",YES,Non-Small Cell Lung Cancer,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Pemetrexed,"Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first., Randomization up to approximately 39 months|Overall Survival (OS), OS is defined as time from randomization to death from any cause., Randomization up to approximately 39 months","Overall Survival Rate at Year 1, The Overall Survival Rate at the 1-year landmark time point is defined as the probabilities that participants are alive 1-year after randomization., Year 1|Overall Survival Rate Year 2, The Overall Survival Rate at the 2-year landmark time point is defined as the probabilities that participants are alive 2-years after randomization., Year 2|Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1, An objective response is defined as either an unconfirmed CR or a PR, as determined by the investigator using RECIST v1.1. Objective Response Rate is defined as the proportion of patients who had an objective response., Randomization up to approximately 25 months|Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1, DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first., Randomization up to approximately 25 months|Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score, EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998)., Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)|Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score, The EORTC QLQ-LC13 module incorporates one multiple item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998)., Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)|Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score, Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \& 2, 'Cough' score is mean of question 3 \& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea \& cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant., Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)|Minimum Observed Serum Atezolizumab Concentration (Cmin), Minimum observed serum atezolizumab concentration (Cmin) prior to infusion at selected cycles (Arm A), Predose (Prd; 0 hour [h]) on D1 of Cy 2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle (up to approximately 25 months)|Maximum Observed Serum Atezolizumab Concentration (Cmax), Maximum observed serum atezolizumab concentration (Cmax) after infusion (Arm A), Day 1 of Cycle 1 (Cycle length=21 days)|Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed), Prd (0 h), 5-10 minutes (mins) before end of carboplatin infusion (infusion duration=1-2 h), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)|Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed), Prd (0 h), 5-10 mins before end of cisplatin infusion (infusion duration=30-60 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)|Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed), Prd (0 h), 5-10 mins before end of pemetrexed infusion (infusion duration=10 mins), 1 h post-infusion on D1 of Cy1,3 (Cy length=21 days)|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab, Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed), Prd (0 h) on D1 of Cy1,2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle, at treatment discontinuation & then every 30 days (up to 120 days) after last dose of atezolizumab (up to app 25 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,578,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GO29438|2015-003605-42,2016-04-30,2019-07-18,2022-12-13,2016-01-15,2020-10-09,2023-11-21,"Los Angeles Hematology Oncology Medical Group, Los Angeles, California, 90017, United States|St. Joseph Heritage Healthcare, Sebastopol, California, 95472, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, 06904, United States|Orlando Health Inc., Orlando, Florida, 32806, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, 32308, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|HealthCare Research Network II, LLC - PPDS, Tinley Park, Illinois, 60487, United States|Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, 46845, United States|Goshen Health System, Goshen, Indiana, 46526, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, 40536, United States|University of Michigan, Ann Arbor, Michigan, 48109-0934, United States|CHI Health St. Francis, Grand Island, Nebraska, 68803, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Montefiore Medical Center, Bronx, New York, 10461, United States|Swedish Cancer Institute, Cary, North Carolina, 27513, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, 17325, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212, United States|Oncology Consultants PA, Houston, Texas, 77030, United States|Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, 22031, United States|Peninsula Cancer Institute, Newport News, Virginia, 23601, United States|Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|University of Washington, Seattle, Washington, 98195, United States|St. Vincent Hospital, Green Bay, Wisconsin, 54311, United States|Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, 00001428, Argentina|Fundacion Clinica Colombo, Cordoba, X5002AOQ, Argentina|Clinica Viedma S.A., Viedma, R8500ACE, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Sydney Adventist Hospital; Clinical Trial Unit, Sydney, New South Wales, 2076, Australia|St George Hospital; Medical Oncology, Sydney, New South Wales, 2217, Australia|Redcliffe Hospital, Redcliffe, Queensland, 4020, Australia|Mater Adult Hospital, South Brisbane, Queensland, 4101, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Ballarat Health Services, Ballarat, Victoria, 3350, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, 3199, Australia|Barwon Health, Geelong, Victoria, 3220, Australia|Klinikum Wels-Grieskirchen GmbH, Wels, 4600, Austria|AZ Maria Middelares, Gent, 9000, Belgium|Clinique André Renard; Pneumologie, Herstal, 4040, Belgium|AZ Delta (Campus Rumbeke), Apotheek, Roeselare, 8800, Belgium|Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, 1303, Bulgaria|Health & Care SPA, Santiago, 7500006, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, 4800827, Chile|Hospital Clinico Vina del Mar?, Viña del Mar, 2520612, Chile|Beijing Friendship Hospital Affiliated of Capital University of Medical Science, Beijing Shi, 100050, China|Beijing Cancer Hospital, Beijing, 100142, China|Hunan Cancer Hospital, Changsha CITY, 410013, China|Changzhou First People's Hospital, Changzhou, 213003, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou City, 310003, China|Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, 310016, China|Anhui Provincial Hospital; 2F,Tumor chemotherapy Department, Hefei, 230001, China|Anhui Provincial Hospital; Respiratory Department, Hefei, 230088, China|Qilu Hospital, Jinan City, 250012, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, 210029, China|Shanghai Chest Hospital, Shanghai, 200000, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|First Hospital of China Medical University, Shenyang, 110001, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, 3000060, China|Tianjin Medical University General Hospital, Tianjin, 300052, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, 430030, China|Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430023, China|Zhejiang Cancer Hospital, Zhejiang, 310022, China|Institut Sainte Catherine, Avignon, 84082, France|Hopital Louis Pradel; Pneumologie, Bron, 69677, France|Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne, Clermont-ferrand, 63003, France|Centre Hospitalier Intercommunal; Service de Pneumologie, Creteil, 94010, France|Polyclinique de Limoges - Site Chenieux; Oncologie Medicale, Limoges, 87039, France|Hopital Nord AP-HM, Marseille, 13015, France|Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque; Service d oncologie, Montpellier, 34298, France|Centre Hospitalier de Mulhouse - Hopital Emile Muller, Mulhouse, 68070, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, 94160, France|Hopital d Instruction des Armees de Sainte Anne, Toulon, 83041, France|Veszprem Megyei Tudogyogyintezet, Farkasgyepu, 8582, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, 9024, Hungary|Markusovszky Hospital, Szombathely, 9700, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, 8000, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, 2045, Hungary|Mater Misecordiae University Hospital, Dublin, 7, Ireland|St James's Hospital, Dublin, 8, Ireland|Barzilai Medical Center, Ashkelon, 7830604, Israel|Edith Wolfson Medical Center, Holon, 5822012, Israel|Rabin Medical Center, Petach Tiqwa, 4941492, Israel|Azienda Ospedaliero Universitaria di Parma, Parma, Emilia-Romagna, 43126, Italy|Ospedale Santa Maria Delle Croci, Ravenna, Emilia-Romagna, 48100, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, 00144, Italy|Azienda Policlinico Umberto I, Roma, Lazio, 00161, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, 10043, Italy|Presidio Ospedaliero Vito Fazzi; Unita Operativa Di Oncologia Medica, Lecce, Puglia, 73044, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Puglia, 71013, Italy|Ospedale San Vincenzo Taormina :Divisione di Oncologia Medica, Taormina, Sicilia, 98039, Italy|Ospedale San Luca - USL2 Lucca, Lucca, Toscana, 55100, Italy|National Hospital Organization Nagoya Medical Center, Aichi, 460-0001, Japan|National Cancer Center Hospital East, Chiba, 277-8577, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|National Hospital Organization Asahikawa Medical Center, Hokkaido, 070-8644, Japan|National Hospital Organization Himeji Medical Center, Hyogo, 670-8520, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|Kanagawa Cancer Center, Kanagawa, 241-8515, Japan|Tohoku University Hospital, Miyagi, 980-8574, Japan|Niigata University Medical & Dental Hospital, Niigata, 951-8520, Japan|Osaka University Hospital, Osaka, 565-0871, Japan|Osaka Medical and Pharmaceutical University Hospital, Osaka, 569-8686, Japan|Saga University Hospital, Saga, 849-8501, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Juntendo University Hospital, Tokyo, 113-8431, Japan|Nippon Medical School Hospital, Tokyo, 113-8603, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|NTT Medical Center Tokyo, Tokyo, 141-8625, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, 755-0241, Japan|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, LV-1079, Latvia|Panevezys Hospital, Panevezys, 35144, Lithuania|Hospital Kuala Lumpur, Kuala Lumpur, FED. Territory OF Kuala Lumpur, 50586, Malaysia|Advanced Medical and Dental Institute; Kompleks Klinikal, Kepala Batas, Penang, 13200, Malaysia|Amphia Ziekenhuis, Breda, 4819 EV, Netherlands|Haga Ziekenhuis, Den Haag, 2547 EX, Netherlands|Ziekenhuis Gelderse Vallei, EDE, 6716 RP, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, 3844 DG, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, 6162 BG, Netherlands|ETZ TweeSteden, Tilburg, 5042AD, Netherlands|Hospital Nacional Cayetano Heredia, Lima, 31, Peru|Hospital Beatriz Angelo, Loures, 2674-514, Portugal|Unidade Local de Saude de Matosinhos SA, Matosinhos, 4454-509, Portugal|Hospital CUF Porto; Servico de Imunoalergologia, Senhora Da Hora - Porto, 4460-188, Portugal|Medisprof SRL, Cluj-Napoca, 400058, Romania|Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, 900591, Romania|Euroclinic Center of Oncology SRL, Iasi, 700106, Romania|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Moskovskaja Oblast, 454087, Russian Federation|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, 150040, Russian Federation|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, 03203, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|ICO L'Hospitalet; Servicio de oncologia medica, L'Hospitalet de Llobregat, Barcelona, 08908, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, 8208, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Sant Andreu de La Barca, Barcelona, 08740, Spain|Hospital de Mataro, Mataro, Cantabria, 08304, Spain|Onkologikoa; Ensayos Clinicos, Donostia, Guipuzcoa, 20014, Spain|Centro Oncologico de Galicia COG; Medical Oncology, A Coruna, LA Coruña, 15009, Spain|Hospital Universitario Virgen de La Arrixaca; Servicio De Oncologia, El Palmar, Murcia, 30120, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, 31008, Spain|Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona, Navarra, 31008, Spain|Complejo Hospitalario Nuestra Senora de Valme, Seville, Sevilla, 41014, Spain|Hospital General Univ. de Alicante, Alicante, 03010, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, 08028, Spain|C.A.U de Burgos- Hospital Universitario de Burgos; Servicio de Oncologia, Burgos, 09006, Spain|Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica, Girona, 17007, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, 27003, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|HM Sanchinarro ? CIOCC, Madrid, 28050, Spain|Hospital Regional Universitario de Malaga ? Hospital General; Servicio de Neurologia, Malaga, 29010, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, 46026, Spain|Buddhist Dalin Tzuchi General Hospital, Dalin, Chiayi, 622, Taiwan|E-DA Hospital; Chest, Kaohsiung, 824, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, 736, Taiwan|Taipei Veterans General Hospital, Taipei City, 112, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, 100, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan|MI Dnipropetrovsk City Multifield Clinical Hospital 4 of Dnipropetrovsk Regional Council, Dnipropetrovsk, Katerynoslav Governorate, 49102, Ukraine|Kyiv Railway Clinical Hospital #3 of Branch Health Center of PJSC Ukrainian Railway; Surgery Dept, Kyiv, Kharkiv Governorate, 02096, Ukraine|MICR Oncology Dispensary of Cherkasy Regional Council; Regional Center of Clinical Oncology, Cherkasy, 18009, Ukraine|Private Enterprise Private Manufacturing Company Acinus, Kirovograd, 25006, Ukraine|Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary; Oncothoracic department, Sumy, 40022, Ukraine|MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology, Zaporizhzhya, 69040, Ukraine|Bristol Haematology and Oncology centre, Bristol, BS2 8ED, United Kingdom|Velindre Hospital, Cardiff, CF14 2TL, United Kingdom|Gartnavel General Hospital; Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Raigmore Hospital, Inverness, IV2 3UV, United Kingdom|St George?s Hospital, London, SW17 ORE, United Kingdom|Charing Cross Hospital, London, W6 8RF, United Kingdom|Churchill Hospital, Oxford, OX3 7LJ, United Kingdom|Derriford Hospital; Plymouth Oncology Centre, Plymouth, PL6 8DH, United Kingdom|Queen's Hospital, Romford, RM7 0AG, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LQ, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/34/NCT02657434/Prot_002.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/34/NCT02657434/SAP_001.pdf"
